The Epstein-Barr virus (EBV)-encoded EBNA1 protein is expressed in all virus-associated tumors where it plays an essential role in the maintenance, replication and transcription of the EBV genome. Transcriptional profiling of EBNA1-expressing carcinoma cells demonstrated that EBNA1 also influences the expression of a range of cellular genes including those involved in translation, transcription and cell signaling. Of particular interest was the ability of EBNA1 to enhance expression of STAT1 and sensitize cells to interferon-induced STAT1 activation with resultant enhancement of major histocompatibility complex expression. A negative effect of EBNA1 on the expression of TGFb1-responsive big-h3 and PAI-1 genes was confirmed at the protein level in EBV-infected carcinoma cells. This effect resulted from the ability of EBNA1 to repress TGFb1-induced transcription via a reduction in the interaction of SMAD2 with SMAD4. More detailed analysis revealed that EBNA1 induces a lower steady-state level of SMAD2 protein as a consequence of increased protein turnover. These data show that EBNA1 can influence cellular gene transcription resulting in effects that may contribute to the development of EBV-associated tumors.
Introduction
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus associated with the development of both lymphoid and epithelial tumors . The pattern of EBV latent protein expression in these tumors is different from that observed in EBVtransformed lymphoblastoid cell lines (LCLs) Raab-Traub, 2002; Young and Rickinson, 2004) . Thus, only EBNA1 is expressed in Burkitt's lymphoma (BL), while EBNA1 and two membrane proteins (LMP1 and LMP2A/B) are expressed in Hodgkin's lymphoma (HL) and nasopharyngeal carcinoma (NPC) Raab-Traub, 2002) . This consistent expression of EBNA1 results from its central role in the maintenance and replication of the episomal EBV genome, which is achieved through sequence-specific binding to the plasmid origin of viral replication, oriP . EBNA1 can also interact with certain viral promoters thereby contributing to the transcriptional regulation of the EBNAs (including EBNA1 itself) and of LMP1. The EBNA1 protein is separated into N-and C-terminus domains by a glycine-glycinealanine (gly-ala) repeat sequence, whose main function appears to be to stabilize the mature protein from proteasomal breakdown rather than to act in its originally perceived role as an immune evasion domain (Levitskaya et al., 1995; Lee et al., 2004; Tellam et al., 2004; Voo et al., 2004) .
Studies using a dominant-negative version of EBNA1 in an LCL with an integrated copy of the EBV genome revealed no effect of EBNA1 on cell growth or cellular gene expression (Kang et al., 2001) . This is supported by the observation that a recombinant EBV (rEBV) deleted for EBNA1 remains capable of transforming B cells but at a significantly reduced efficiency (Humme et al., 2003) . Other studies in which EBNA1 has been expressed in Akata BL cells previously cleared of EBV infection demonstrated that EBNA1 alone is not sufficient to confer tumorigenic potential to these BL cells (Komano et al., 1998; Ruf et al., 2000) . However, a more direct involvement in oncogenesis has been suggested by the ability of B-cell-directed EBNA1 expression to produce B-cell lymphomas in transgenic mice, although this effect is controversial (Wilson et al., 1996; Kang et al., 2005) , and by its possible contribution to BL cell survival in vitro (Kennedy et al., 2003) . EBNA1 was recently shown to interact with a ubiquitinspecific protease called USP7 or HAUSP that has been previously implicated in the stabilization of p53 (Holowaty et al., 2003) . Subsequent structural analysis has revealed that EBNA1 binds with higher affinity to the same region of USP7 as p53 and MDM2 (Saridakis et al., 2005; Sheng et al., 2006) . Functional consequences of these interactions have been suggested by the ability of EBNA1 to protect from either UV-or p53-induced apoptosis (Kennedy et al., 2003; Saridakis et al., 2005) .
Given these effects and the ability of EBNA1 to function as a transcriptional activator of several viral genes, it is likely that EBNA1 will also be able to influence cellular gene expression. This has already been demonstrated in the context of B cells, where EBNA1 has been shown to induce CD25 expression in an EBV-negative HL cell line and to upregulate RAG1 and RAG2 expression in a BL cell line (Srinivas and Sixbey, 1995; Kube et al., 1999) . To examine the possible role of EBNA1 in EBVassociated carcinogenesis, we performed transcriptional profiling analysis of EBNA1-expressing carcinoma cells and identified a number of significant changes. These studies reveal, for the first time, a role for EBNA1 in modulating the behavior of two signal transduction pathways with important roles in the oncogenic process.
Results

EBNA1 modulates the transcription of a wide variety of cellular genes
To assess the potential effect of EBNA1 expression on cellular gene transcription in an epithelial cell environment, we generated Ad/AH carcinoma cells stably expressing EBNA1 for subsequent gene profiling analysis. Transfection of EBNA1 resulted in higher levels of expression than that seen in Ad/AH cells infected with a rEBV or in the C666-1 EBV-positive NPC cell line ( Figure 1a) . Subsequent gene profiling analysis revealed 113 upregulated and 49 downregulated genes using a cut-off X1.5-fold across three replicate analyses ( Figure 1a , Supplementary Table 1 ). These differences were confirmed at the reverse transcription (RT)-PCR and protein levels across a range of genes involved in diverse cellular functions such as translational regulation (EEF1A2, EIF4G1, TFIIIC), cell signaling and apoptosis (BAG3, ID2, STAT1, big-H3) and cell adhesion (ICAM1, SPOCK) (Figure 1b) .
EBNA1 enhances the expression and activity of STAT1
The validation analysis confirmed that STAT1 expression was induced in EBNA1-expressing Ad/AH. Stable EBNA1 expression in both the HONE-1 NPC cell line ( Figure 2a ) and in the AGS gastric carcinoma cell line (Figure 2b ) also resulted in increased expression of STAT1. The ability of EBNA1 to induce STAT1 expression was also confirmed in transient transfection assays (Supplementary Figure 1) . These data confirmed the generality of the observed effect of EBNA1 on STAT1 levels and demonstrated that this effect was consistent across a number of carcinoma cell clones expressing comparable levels of EBNA1 to that present in the EBV-positive C666-1 NPC cell line (Figure 2) . Interestingly, while EBNA1 induced both the transcriptionally active STAT1a (p91) isoform and the STAT1b (p84) inhibitory isoform, there appeared to be a preferential induction of STAT1a (p91) (Figure 2a) .
The induction of STAT1 expression by EBNA1 prompted us to examine whether this effect influenced the response of EBNA1-expressing carcinoma cells to treatment with interferon (IFN). Immunoblot analysis confirmed the ability of EBNA1 to upregulate STAT1 expression in Ad/AH cells and demonstrated that this resulted in enhanced induction of phosphorylated STAT1 (pSTAT1) in response to IFNg (Figure 3a) and IFNa (not shown). A similar enhancement of pSTAT1 induction was observed in rEBV-infected Ad/ AH cells as compared to Neo control Ad/AH cells. Interestingly, IFNg treatment also resulted in a robust activation of STAT1 in the C666-1 cell line confirming the integrity of this pathway in NPC cells (Figure 3a) . EBNA1 also induced STAT1 expression, with associated enhancement of IFNg-induced activation, in the EBV-negative HONE-1 and AGS carcinoma cell lines (data not shown). The ability of EBNA1 to enhance IFNg-induced STAT1 signaling was observed at the protein level by enhanced nuclear translocation of STAT1 ( Figure 3b) and at the transcriptional level by increased activity of an IFNg-responsive luciferase reporter containing a STAT1 consensus binding site ( Figure 3c ). This reporter also confirmed the ability of the C666-1 NPC cell line to efficiently respond to IFNg stimulation. To determine the functional consequences of EBNA1-enhanced STAT1 activation in carcinoma cells, the levels of major histocompatibility complex (MHC) expression were determined after IFNg stimulation by immunoblotting. This analysis revealed that EBNA1 enhanced the ability of IFNg to induce both MHC class I and class II in Ad/AH cells expressing EBNA1 (Figure 3d ). IFNg induction of MHC class I expression, but not MHC class II, was also augmented in rEBV-infected Ad/AH cells. While EBNA1 was also found to enhance STAT1 activation in response to IFNa treatment, this did not result in nuclear translocation of STAT1 or in the activation of an IFNa-responsive reporter suggesting that EBNA1 has a differential effect on the IFNg versus the IFNa pathway (Figure 3b ; data not shown).
EBNA1 represses TGFb1-induced gene transcription
The gene most significantly downregulated by EBNA1 in the transcriptional profiling analysis was big-h3, a TGFb1-regulated gene involved in cell growth, differentiation and apoptosis (Oh et al., 2005) . Examination of big-h3 expression in EBNA1-expressing clones of the HONE-1 and AGS carcinoma cell lines confirmed that levels of EBNA1 equivalent to that present in the C666-1 NPC cell line resulted in the downregulation of big-h3 (Figure 2) . RT-PCR analysis and immunoblotting further confirmed that both basal and TGFb1-induced big-h3 expression is reduced in EBNA1-expressing and in rEBV-infected Ad/AH cells (Figure 4a and b) . big-h3 expression was absent in C666-1 cells. A similar ability of EBNA1 to repress basal and TGFb1-induced big-h3 expression was observed in EBNA1-expressing HONE1 and AGS carcinoma cell lines (data not shown). PAI-1 (plasminogen activator inhibitor type I) is a classical target of TGFb1 in epithelial cells (Siegel and Massague, 2003) and immunoblotting revealed that EBNA1 and EBV infection significantly reduced both basal and EBNA1 modulates cell signaling pathways VHJ Wood et al
TGFb1-induced PAI-1 expression (Figure 4c ). The repression of TGFb1-induced big-h3 and PAI-1 expression appeared to be more pronounced in EBV-infected cells as compared to EBNA1-transfected cells suggesting that other EBV-encoded genes may contribute to this effect. Use of a TGFb1-responsive reporter (p3TP-lux) confirmed that both EBNA1 expression and EBV infection impaired both basal and TGFb1-induced transcription (Figure 4d ). Again, no activity of the TGFb1 reporter was observed in C666-1 cells consistent with the lack of both big-h3 and PAI-1 expression. EBNA1 modulates cell signaling pathways VHJ Wood et al EBNA1 affects SMAD2 signaling via increased protein turnover To identify the mechanism underlying the ability of EBNA1 to repress TGFb1 signaling, we examined the integrity of the TGFb1 transduction pathway. RT-PCR analysis ( Figure 5a ) and immunoblotting (data not shown) revealed no alterations in the expression of TGFb1 itself or of its receptors (TbRI and TbRII) in either EBNA1-expressing or rEBV-infected Ad/AH cells. However, the C666-1 NPC cell line lacked expression of TbRII accounting for the impairment of TGFb1 responsiveness in this line ( Figure 5a ). As the SMAD transcription factors mediate TGFb1 signal transduction, we next examined the expression of the receptor-associated SMADs (SMAD2 and SMAD3) and of the interacting SMAD4 protein (Siegel and Massague, 2003) . As SMADs undergo constant nucleocytoplasmic shuffling, we examined their expression in cytoplasmic and nuclear extracts from EBNA1-expressing cells. While no gross differences were observed in the levels or localization of SMAD3 and SMAD4, SMAD2 levels in both the cytoplasm and nucleus were significantly reduced in EBNA1-expressing or rEBVinfected Ad/AH cells as compared to the Ad/AH Neo control cells (Figure 5b ). Consistent with the reduction in SMAD2 expression, both EBNA1 and EBV infection reduced the levels of TGFb1-induced SMAD2 activation as measured by phosphorylation ( Figure 5c ). The inability of C666-1 NPC cells to activate SMAD2 in response to TGFb1 treatment is consistent with the lack of TbRII expression. The activated SMAD complex responsible for subsequent transcriptional regulation of TGFb1-responsive genes consists of either dimers or trimers of phosphorylated SMAD2/3 bound to SMAD4 (Siegel and Massague, 2003) . To examine the effect of EBNA1 on the formation of the activated SMAD complex, we performed immunoprecipitation experiments using antibodies to SMAD2 and SMAD4. TGFb1 induced the interaction of SMAD2 with SMAD4 in control Ad/AH cells as expected, but formation of this complex was significantly impaired in both EBNA1-transfected and rEBV-infected Ad/AH cells ( Figure 5d ). To confirm that the EBNA1-induced reduction in SMAD2 was responsible for the attenuation Immunostaining for STAT1 demonstrates that EBNA1, but not rEBV, enhances both basal expression and nuclear translocation of STAT1 in response to IFNg but not IFNa. Cells were serum starved in 0.5% fetal calf serum (FCS) overnight before 1 h stimulation with 10 ng/ml IFNg or IFNa, or remaining untreated as a control. Following fixation in 4% paraformaldehyde and permeabilization in 0.5% Triton X-100, immunostaining was performed for STAT1. (c) Transient transfection with the luciferase reporter plasmid, GRRS, confirms the ability of EBNA1 but not rEBV in Ad/AH cells to upregulate GAS (IFNg-activated sequence) activity in response to IFNg. Thirty-six hours after transfection, cells were stimulated with 10 ng/ml IFNg for 6 h before harvesting or left unstimulated as a control. Data from three independent experiments are presented as the mean fold differences in activity7s. Immunoblot analysis was performed on TGFb1-treated lines using a phospho-SMAD2-specific antibody. (d) Immunoprecipitation analysis demonstrates that both EBNA1 and rEBV repress SMAD2 and SMAD4 association following TGFb1 stimulation. Cells were serum starved overnight and stimulated for 1 h with 10 ng/ml TGFb1 or left unstimulated as a control before harvesting in TNTE buffer. Either SMAD2 or SMAD4 were immunoprecipitated from samples and analysed by immunoblotting for SMAD4 or SMAD2 association. (e) Transient transfection of Ad/AH EBNA1 cells with the luciferase reporter plasmid p3TP-lux in combination with increasing amounts of FLAG-SMAD2 removes the repressive effect of EBNA1 on TGFb1-induced luciferase activity. Twenty-four hours before harvesting, cells were stimulated with 10 ng/ml TGFb1 or left unstimulated as a control. Data from three independent experiments are presented as the mean fold differences in activity7s.d., relative to that observed in unstimulated Ad/AH Neo control cells which is given an arbitrary value of 1. Immunoblot analysis using a FLAG-specific antibody confirms the expression of FLAG-tagged SMAD2.
EBNA1 modulates cell signaling pathways VHJ Wood et al cells, a more pronounced effect was observed in response to TGFb1 treatment where even low doses of exogenous SMAD2 were able to overcome the inhibitory effect of EBNA1 on TGFb1-mediated transcriptional activity (Figure 5e ). The studies described above show that SMAD2 protein levels are reduced by EBNA1 with consequent attenuation of SMAD2 activation in response to TGFb1. RT-PCR analysis revealed that transcription of SMAD2 and other SMADs was not affected by either EBNA1 expression or EBV infection (Figure 6a and b) suggesting that EBNA1 might affect the turnover of the SMAD2 protein. To examine this possibility, Ad/AH cells were treated with the protein synthesis inhibitor anisomycin for different times before immunoblotting for EBNA1 or SMAD2. This analysis confirmed the stability of the EBNA1 protein and revealed that the SMAD2 protein is more rapidly degraded in Ad/AH cells expressing EBNA1 as compared to the control cells (Figure 6c ). Pooling data from two such experiments confirmed that the half-life of SMAD2 in control cells was 5 h, whereas in the presence of EBNA1 this was reduced to 2.5 h (Figure 6d ).
Discussion
The possibility that EBNA1 has additional functional effects beyond its crucial role in the maintenance and replication of the EBV episome has been suggested for some time. The ability of EBNA1 to transcriptionally regulate viral genes is well accepted and previous reports implicated EBNA1 in the control of specific cellular genes in B cells (Tsimbouri et al., 2002) . This led us to examine the effect of EBNA1 expression on cellular gene expression in carcinoma cells as a model for the possible behavior of this protein in NPC-and EBV-associated gastric carcinoma. A wide variety of functionally distinct genes were regulated by EBNA1 and some of the most significant and reproducible changes were confirmed by RT-PCR analysis and immunoblotting. Thus, we confirmed that EBNA1 is able to regulate the expression of genes associated with translational regulation, cell signaling, apoptosis and cell adhesion. These effects in a carcinoma background may help to explain previous studies in which EBNA1 was found to enhance the malignant progression of NPC cells and to suppress expression of the HER2/neu oncogene in an ovarian carcinoma cell line (Sheu et al., 1996; Chuang et al., 2002) . Taken together with previous studies in both B cells and epithelial cells, the data would suggest that the ability of EBNA1 to influence cellular gene expression and to effect certain functional changes is dependent on both cell type and differentiation status. The KSHVencoded latency-associated nuclear antigen (LANA) behaves like EBNA1 in its ability to support viral episome maintenance, but LANA also has profound effects on cell growth and survival. By interacting with the p53 and pRb tumor suppressors and with GSK-3b, LANA affects cellular gene transcription and recent work in transgenic mice demonstrates that LANA can induce B-cell hyperplasia and lymphomagenesis (Friborg et al., 1999; Radkov et al., 2000; Fujimuro et al., 2003; Fakhari et al., 2006) . Thus, it is not surprising that EBNA1 also functions beyond its role in episome maintenance. While this current study has concentrated on the effects of EBNA1 on the STAT1 and TGFb1 pathways, a variety of other genes were also affected and are currently the focus of on-going studies. For instance, we have preliminary evidence that the induction of TFIIIC102 expression by EBNA1 contributes to the ability of EBV infection to upregulate polIII transcription in carcinoma cells (Arrand et al., unpublished observations) .
Constitutive activation of the STAT pathway commonly occurs in both hematopoietic malignancies and carcinomas as a consequence of either genetic or autocrine/paracrine alterations (Yu and Jove, 2004) . Previous studies have highlighted a role for STATs in regulating EBV gene expression in carcinoma cells and have demonstrated strong nuclear staining for (overexpression of) STAT1 in NPC tissue (Chen et al., 2001 (Chen et al., , 2003 Stewart et al., 2004) . Our data extend these observations by showing that EBNA1 can induce the expression of STAT1 with resultant sensitization of the carcinoma cells to IFN treatment as measured by both enhanced STAT1-mediated transcription and augmented induction of MHC expression. While EBV infection of carcinoma cells also resulted in increased STAT1 activation, this was not reflected at the transcriptional level where both basal and IFN-induced transcription were reduced compared to EBNA1-transfected cells. This is likely to be due to the suppressive effect of LMP2A on the STAT pathway (Stewart et al., 2004) and reflects the complex interplay used by EBV to Figure 6 EBNA1 enhances the turnover of SMAD2. (a) Reverse transcription (RT)-PCR analysis demonstrates that the levels of SMAD2, SMAD3 and SMAD4 are not affected by either EBNA1 expression or recombinant EBV (rEBV) infection in Ad/AH cells and that TGFb1 stimulation also has no effect on SMAD transcription. RT-PCR analysis was performed using the primers described in the Supplementary Information. Analysis of glyceraldehyde phosphate dehydrogenase (GAPDH) was included as a control. (b) Semi-quantitative RT-PCR analysis for SMAD2 further confirms that EBNA1 expression or rEBV infection in Ad/AH cells has no effect on SMAD2 transcription. RT-PCR analysis was performed over 25, 30 and 35 cycles using the primers described in the Supplementary information. Analysis of GAPDH was included as a control. (c) Anisomycin treatment of EBNA1-expressing Ad/AH cells reveals increased SMAD2 turnover relative to the control Ad/AH cell line and confirms the stability of the EBNA1 protein. Cells were treated for the indicated times with anisomycin (10 mg/ml) before immunoblotting for either EBNA1, SMAD2 or actin. (d) Densitometric scanning was performed on the SMAD2 immunoblot representing anisomycin-treated samples and the corresponding actin. Following normalization of densitometry values for SMAD2 against actin, an X and Y scatterplot was generated illustrating the half-life of SMAD2 in Ad/AH EBNA1 cells compared with Ad/AH Neo control cells. The graph represents data from two independent experiments. EBNA1 modulates cell signaling pathways VHJ Wood et al modulate both cellular and viral gene expression. Consistent with the presence of activated STAT1 in NPC biopsies, the C666-1 NPC cell line gave a robust response to IFNg treatment. The precise role of STAT1 in the oncogenic process is unknown, and it has been suggested that it may act as either a tumor suppressor or a tumor promoter (Yu and Jove, 2004; Kovacic et al., 2006) . Given the role of inflammation in the pathogenesis of cancer, it is possible that STAT1 contributes to this process by mediating the proinflammatory activity of the IFNs (Balkwill and Mantovani, 2001 ). This would suggest an early role for EBNA1-induced STAT1 in the EBNA1 modulates cell signaling pathways VHJ Wood et al carcinogenic process consistent with the upregulation of this molecule in hyperplastic skin lesions (Haider et al., 2006) . In this context, it would be interesting to examine STAT1 (both STAT1a and STAT1b isoforms) at both the expression and functional levels in premalignant and invasive NPC lesions. Unlike other squamous carcinomas where STAT1 levels are frequently reduced as a consequence of promoter methylation (Xi et al., 2006 ), NPC appears to be unusual in maintaining active STAT1 (possibly as a consequence of EBNA1 expression) and this may contribute both to the unusual cellular phenotype of these cells (for example, high levels of MHC expression) and to their restricted pattern of EBV latent gene expression as STATs are required for both EBNA1 (Q promoter driven) and LMP1 expression (Chen et al., 1999 (Chen et al., , 2003 .
The most significantly downregulated gene in response to EBNA1 expression in the Ad/AH carcinoma cell line was big-h3, a TGFb1-induced extracellular matrix protein involved in cell adhesion, differentiation and apoptosis (Nam et al., 2005; Oh et al., 2005) . The big-h3 gene is mutated in both familial and sporadic corneal dystrophies and has recently been implicated in the regulation of antigen uptake by immature dendritic cells (Munier et al., 1997; Cao et al., 2006) . In the context of cancer, big-h3 may function as a tumor suppressor by promoting epithelial differentiation and inhibiting tumor angiogenesis and has recently been shown to be epigenetically inactivated in a range of different tumors (Nam et al., 2005; Oh et al., 2005; Shao et al., 2006) . The downregulation of basal and TGFb1-induced big-h3 by EBNA1 was confirmed at the RNA and protein level in both EBNA1-transfected and EBVinfected carcinoma cells. This suggested that EBNA1 might have a global effect in antagonizing the TGFb1 pathway, a contention supported by the ability of EBNA1 to also inhibit basal and TGFb1-induced expression of PAI-1, a classical TGFb1-responsive gene (Siegel and Massague, 2003) . ID2, a transcriptional regulator widely implicated in oncogenesis, is a welldocumented target of repression by TGFb1 (Perk et al., 2005) and was found to be induced by EBNA1 expression in this study. Thus, it is possible that EBNA1 contributes to the high levels of ID2 observed in NPC and the EBV-associated forms of HL and BL (Chow et al., 2006; Renne et al., 2006) . Our subsequent analysis revealed that the ability of EBNA1 to impair TGFb1 signaling was manifest at the level of TGFb1 target gene transcription suggesting the possible involvement of the SMAD transcription factors. More detailed examination demonstrated that EBNA1 expression resulted in a reduction in SMAD2 expression and an associated impairment of the formation of the activated SMAD complex in response to TGFb1 stimulation. Several oncogenic viruses including HPV, HTLV-1, HBV, HCV and KSHV encode gene products that modulate the TGFb signaling pathway mainly via interactions with SMAD proteins Seo et al., 2005; Choi and Hwang, 2006) . We found, however, that EBNA1 did not complex with SMAD proteins but was able to promote the turnover of the SMAD2 protein. The receptor activated SMADs are subject to selective ubiquitin-mediated degradation directed by E3 ubiquitin ligases such as Smurf2 and NEDD4-2 (Lo and Massague, 1999; Kuratomi et al., 2005) . This raises the possibility that EBNA1 affects the ubiquination of SMAD2 by regulating E3 ubiquitin ligase activity. A precedent for this in the context of another oncogenic virus is provided by the HPV E6-interacting E3 ligase E6AP, which mediates the ability of the E6 oncoprotein to target p53 for degradation (Huibregtse et al., 1991) . Interestingly, our gene profiling analysis of EBNA1-expressing Ad/AH cells revealed upregulation of the UBE2E3 ubiquitin-conjugating enzyme, which has previously been shown to complex with NEDD4-2 (Debonneville and Staub, 2004) , suggesting a possible mechanism that merits further investigation. A recent study demonstrated that the HSV1 latency-associated transcript encodes a microRNA (miR-LAT) that downregulates both TGFb1 and SMAD3 expression thereby protecting cells from apoptosis (Gupta et al., 2006) . This effect may contribute to the survival of latently infected cells and to the persistence of HSV1 infection. A similar role for EBNA1 in attenuating the apoptotic response to TGFb1 may contribute to the survival of persistently infected cells.
While the TGFb signaling pathway has diverse effects on many aspects of cellular behavior, its prime role is to limit epithelial proliferation and induce differentiation. This tumor suppressor type function of TGFb signaling is evaded in many tumors by the development of mutations in the genes encoding either TGFb receptors or the SMADs (Siegel and Massague, 2003) . As mutations in TbRII have been found in a proportion of NPC cases (Harn et al., 2002) , the precise role of EBNA1-mediated repression of the TGFb pathway in the carcinogenic process remains unclear. It may be that EBNA1, along with other EBV-encoded proteins such as LMP1 and LMP2A which have been shown to repress TGFb signaling (Mori et al., 2003; Fukuda and Longnecker, 2004) , facilitates the evasion of the TGFbdependent cytostatic effect during the initial stages of EBV infection. In this context, EBNA1 may also overcome the ability of TGFb to repress the promoter (Qp) responsible for EBNA1 transcription in NPC cells (Liang et al., 2000) and to activate the EBV replicate cycle via induction of the BZLF1 lytic switch gene (Liang et al., 2002) , thereby facilitating the establishment and maintenance of virus latency.
Recent data suggest that EBNA1 can directly promote the survival of EBV-infected cells and that this may contribute to EBV-associated oncogenesis (Kennedy et al., 2003) . The observation that EBNA1 interacts with the USP7 deubiquitinating enzyme indicates that some of the effects of EBNA1 may be a consequence of sequestering proteins (Holowaty et al., 2003) . More recent structural and functional analysis suggests that EBNA1 competes with both p53 and MDM2 for binding to USP7 and that this may contribute to the survival of EBV-infected cells (Saridakis et al., 2005; Sheng et al., 2006) . Our data further emphasises the cellular effects of EBNA1 particularly in the relation to the regulation of the STAT1 and TGFb1 pathways, two pathways intimately involved in inflammatory responses and carcinogenesis. The precise mechanisms regulating EBNA1-induced upregulation of STAT1 expression and of SMAD2 degradation remain to be elucidated but suggest that this viral protein may have distinct effects on a number of different cellular pathways relevant to both the establishment of persistent EBV infection and to the development of virus-associated tumors.
Materials and methods
Cell lines and tissue culture Ad/AH (a human adenocarcinoma cell line derived from the nasopharynx), HONE-1 (an EBV-negative NPC cell line), AGS (a gastric carcinoma cell line) and C666-1 (a cell line derived from an undifferentiated EBV-positive NPC) were cultured in RPMI medium 1640 supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and 1% penicillinstreptomycin solution (Sigma-Aldrich, Poole, Dorset, UK). Ad/AH cells stably infected with rEBV were generated as described previously (Stewart et al., 2004) . To generate EBNA1-positive cells, the cell line panel (Ad/AH, HONE-1, AGS) was transfected with either control ZIPSV(X)1-neo plasmid or ZIPSV(X)1-neo-EBNA1 and following 4 weeks of drug selection with 400 mg/ml G418, clones were isolated and screened for EBNA1 expression. Cells were grown in either T 75 flasks for RNA extraction for the microarray; 6-cm dishes for TGFb1 and IFNg stimulations, anisomycin (10 mg/ml) treatment, RT-PCR and immunoblot analysis; six-well plates for transient transfections or in 10 cm dishes for immunoprecipitation.
Gene expression analysis
Affymetrix Human Genome Focus Arrays were used for all experiments. Total RNA was extracted in triplicate from mycoplasma free cells using EZ-RNA total RNA isolation kit (Geneflow, Staffordshire, UK) and was used to prepare biotinylated RNA. A complete description of procedures is available at http://bioinf.picr.man.ac.uk/mbcf/downloads/ GeneChip_Target_Prep_Protocol-CR-UK_v2.pdf. Ratios for glyceraldehyde phosphate dehydrogenase (GAPDH) and bactin (3 0 /5 0 ) were within acceptable limits (GAPDH, 0.79-0.97; b-actin, 0.88-1.13), and BioB spike controls were present, with BioC, BioD and CreX also present in increasing intensity. Images of GeneChips were analysed using Affymetrix Microarray Suite5.0. Probe level quantile normalization and robust multiarray analysis on the raw .CEL files were performed using the Affymetrix package of the Bioconductor (http:// www.bioconductor.org) project as described previously (Baumforth et al., 2005) . Differentially expressed probe sets were identified using significance analysis of microarrays with the fold change threshold set to 1.5 and the lowest false discovery rate (the q-value) below 5% (Tusher et al., 2001) .
Preparation of nuclear and cytosolic extracts and immunoprecipitation Cells were grown to 80% confluence, and lysed with 200 ml of hypotonic buffer (20 mM Hepes pH 7.0, 10 mM KCl, 1 mM MgCl 2 , 0.5 mM DTT, 0.1% Triton X-100, 20% glycerol). Lysates were disrupted with 20 strokes with a Dounce Homogeniser and centrifuged at 3000 r.p.m. for 5 min at 41C. The supernatant or cytosolic fractions were transferred to fresh eppendorfs. Pellets were resuspended in 100 ml ice-cold extraction buffer (20 mM Hepes pH 7.0, 10 mM KCl, 1 mM MgCl 2 , 0.5 mM DTT, 0.1% Triton X-100, 20% glycerol, 420 mM NaCl) and incubated at 41C for 20 min on a rotating wheel. Following centrifugation at 15 000 r.p.m. for 10 min at 41C to pellet the nuclear matrix, the nuclear fractions were transferred to fresh eppendorfs. Samples were analysed by immunoblotting. For immunoprecipitation experiments, cells were washed twice with ice-cold phosphate-buffered saline (PBS) and lysed in TNTE buffer (20 mM Tris-HCl (pH7.5), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 0.5% Triton X-100, 50 mM NaF, 10 mM Na 4 P 2 O 7 , 20 mM phenylmethylsulfonyl fluoride, 10 mM sodium orthovanadate). Following sonication and centrifugation at 35 000 r.p.m. for 30 min, 1 mg of protein lysates was pre-cleared with protein G-agarose beads (Sigma) before overnight incubation with appropriate antibodies (SMAD2, BD Biosciences; SMAD4, Calbiochem and Laminin-5, Santa Cruz Biotechnologies). The following day antigen-antibody complexes were isolated from protein G-agarose beads. After extensive washing, bound proteins were released with SDS-PAGE sample buffer and analysed by immunoblotting.
Luciferase assays and transient transfection For luciferase assays, the dual luciferase reporter assay (Promega, Madison, WI, USA) was performed according to manufacturer's instructions. Cells were transiently transfected by Lipofectamine (Invitrogen, Paisley, UK) with the control reporter plasmid pGL3-basic, GRRS an IFNg-responsive reporter plasmid containing a STAT1 binding site or p3TP-lux a TGFb1-responsive reporter plasmid that contains three repeats of a 12-O-tetradecanoylphorbol 13-acetate response element and a fragment from positions À636 to À740 of the human PAI-1 promoter. p3TP-lux was kindly proved by Dr J Massague (Memorial Sloan-Kettering Cancer Center, New York, NY, USA). To normalize transfection efficiencies, a TK promoter-driven Renilla luciferase plasmid (Promega) was co-transfected as an internal control. Total amounts of DNA for various transfections were equalized by the addition of an empty vector. Cells were fed 3 h later with equal volumes of RPMI containing 10% FCS and incubated for an additional 17 h. Thereafter, cells were washed with PBS twice and incubated for 6 h in the absence or presence of 10 ng/ml IFNg in RPMI containing 0.5% FBS for GRRS transfections or incubated for 24 h in the absence or presence of 10 ng/ml TGFb1 in RPMI containing 0.5% FBS for p3TP-lux transfections. All assays were carried out in triplicate and represented as mean s.d. of three independent transfections.
